Publications by authors named "A Gozzini"

Restrictive cardiomyopathy (RCM) is characterized by restrictive ventricular pathophysiology determined by increased myocardial stiffness. While suspicion of RCM is initially raised by clinical evaluation and supported by electrocardiographic and echocardiographic findings, invasive hemodynamic evaluation is often required for diagnosis and management of patients during follow-up. RCM is commonly associated with a poor prognosis and a high incidence of heart failure, and PH is reported in paediatric patients with RCM.

View Article and Find Full Text PDF
Article Synopsis
  • - Patients with chronic myeloid leukemia (CML) treated with nilotinib or ponatinib have a risk of arterial occlusive events (AOEs), prompting recommendations for cardiovascular risk assessments before starting treatment.
  • - A study of 455 CML patients showed that using the updated SCORE2/SCORE2-OP algorithm, which accounts for various cardiovascular risk factors, identified a greater percentage of patients at high risk compared to the older SCORE method.
  • - Those classified as high to very high risk under SCORE2/SCORE2-OP experienced a significantly higher incidence of AOEs, emphasizing the algorithm's importance in guiding treatment decisions and enhancing patient care management.
View Article and Find Full Text PDF

Unmet needs remain in later lines chronic myeloid leukemia (CML): the response rate and the overall survival of resistant patients in the chronic phase who changed a second-generation TKI in the second line with another TKI with similar action are usually poor, while the off-target toxicities and the potential development of mutations increase. The recent approval of asciminib, a STAMP inhibitor, in the third line, has the potential to soon change the therapeutic algorithm for this subset of patients. Here, we report the results of a GIMEMA survey assessing the number of patients currently treated in the third line in Italy, the current approach in later lines by Italian physicians, and the future role of this drug according to the reason to switch to asciminib (resistance and/or intolerance), as well as the perceptions about the future position of this agent.

View Article and Find Full Text PDF